Judge approves Bayer's $7.25 billion Roundup cancer settlement

On Friday, November 20, 2026, a Missouri state court judge granted final approval to Bayer's settlement of the Roundup weedkiller cancer litigation, a deal worth up to $7.25 billion. St. Louis Circuit Judge Timothy Boyer's order resolves tens of thousands of US lawsuits that accused Bayer of failing to warn that the herbicide could cause non-Hodgkin lymphoma.
The settlement, first announced in February 2026, was filed in the St. Louis court that has hosted a large share of the US Roundup docket and is home to Bayer's North America Crop Science division. Under the approved terms, the company pays up to $7.25 billion over two decades to resolve the current claims, and the deal also sets up a separate $1 billion security fund meant to protect against funding shortfalls. More than $400 million is earmarked as additional compensation for claimants with special circumstances, according to St. Louis Public Radio.
Related reading: Lukoil general license extension keeps sale window open.
The agreement applies both to Roundup users who are already ill and to people diagnosed with non-Hodgkin lymphoma in the future, which means a portion of the liability is forward-looking rather than closed. Bayer has a two-decade payout schedule, so the cash flows out of the balance sheet gradually rather than in a single quarter.
In his written judgment granting approval, Boyer said the average individual payouts are fair and adequate and that the total dollar amount ranks among the largest in the history of mass tort personal-injury class action settlements. The finding is notable because the deal was not uncontested. Some cancer patients contend the payouts are too small, while others argue the settlement is better than recovering nothing, a calculation that became more pressing after the US Supreme Court ruled in June 2026 that thousands of Roundup lawsuits could not proceed.
Related reading: Medicare Part B premium 2027: $209.40, up $6.50 from $202.90.
That June 25 ruling shifted the negotiating position in Bayer's direction. The company has long denied the claims and has pointed to studies showing glyphosate, Roundup's active ingredient since the product's 1974 launch, is safe. Regulators have split on the question: the World Health Organization's International Agency for Research on Cancer classified glyphosate as probably carcinogenic in 2015, while the US Environmental Protection Agency has said it is not likely to cause cancer in humans when used as directed.
Bayer inherited the Roundup exposure when it bought Monsanto in 2018, and roughly 200,000 Roundup-related claims have been made against the company, mostly by home users, according to the Associated Press. Bayer has already stopped using glyphosate in Roundup sold in the US residential lawn and garden market.
Related reading: OpenAI $30 billion funding $1.25 trillion valuation: $11B close.
Bayer CEO Bill Anderson said in a statement that the court-approved settlement is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation. For investors, the approval removes an overhang that has weighed on the stock for close to a decade, but it does not fully close the chapter. The order can be appealed, the future-claims component remains open, and the two-decade payout means the liability is spread across many reporting periods.
Related reading: Major Richard Star Act passes House 392-18: what the veterans concurrent pay change costs and what comes next.
Bayer's shares trade in Frankfurt under the ticker BAYN, and investors read the court approval as a step toward containing legal costs rather than a one-time reset. The next dated milestones are the claims and distribution process that begins under the approved terms and any appeal of the order, with payments scheduled to run through the two decades of the payout plan. This content is for informational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Consult a qualified financial advisor before making investment decisions.
Get daily intelligence delivered
Create a free account for the Daily Brief every weekday and The Week Ahead every Sunday. No card required.